A placebo controlled study evaluating the effectiveness of medication in preventing winter depressive episodes in patients with a history of Seasonal Affective Disorder
A 7-Month Multicenter, Parallel, Double-Blind, Placebo-Controlled Comparison of 150-300mg/day of Extended-release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Depressive Episodes in Subjects with a History of Seasonal Affective Disorder Followed by an 8-week Observational Follow-up Phase
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
250
Bupropion hydrochloride will be available in dose strength of 150 and 300 milligram (mg). Subjects will receive one tablet of 150 mg bupropion hydrochloride from Day 1 to 7, from Day 8 to Week 27 will receive one tablet of 300 mg bupropion hydrochloride and from Week 28-29 one tablet of bupropion hydrochloride
End of season depression-free rate.
Time frame: 7 months
Time to onset of a seasonal depressive episode.Change from randomization on SIGH-SAD and HAMD-17.
Time frame: 7 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
GSK Investigational Site
Anchorage, Alaska, United States
GSK Investigational Site
Hamden, Connecticut, United States
GSK Investigational Site
Newark, Delaware, United States
GSK Investigational Site
Wilmington, Delaware, United States
GSK Investigational Site
Washington D.C., District of Columbia, United States
GSK Investigational Site
Boise, Idaho, United States
GSK Investigational Site
Edwardsville, Illinois, United States
GSK Investigational Site
Hoffman Estates, Illinois, United States
GSK Investigational Site
Northfield, Illinois, United States
GSK Investigational Site
Oak Brook, Illinois, United States
...and 38 more locations